Letter to the Editor Open Access
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Jul 20, 2021; 11(4): 228-230
Published online Jul 20, 2021. doi: 10.5662/wjm.v11.i4.228
Simplified figure to present direct and indirect comparisons: Revisiting the graph 10 years later
Valeria Fadda, Laura Bartoli, Elisa Ferracane, Sabrina Trippoli, Andrea Messori, HTA, ESTAR Toscana, Firenze 50132, Italy
ORCID number: Valeria Fadda (0000-0002-5048-8812); Laura Bartoli (0000-0002-3283-0987); Elisa Ferracane (0000-0001-6888-8040); Sabrina Trippoli (0000-0002-5762-1807); Andrea Messori (0000-0002-5829-107X).
Author contributions: Fadda V and Messori A were the main contributors of this paper; The other authors were involved in checking the manuscript, identifying inconsistencies, and generating the figure.
Conflict-of-interest statement: The authors declare no conflicts of interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Andrea Messori, BCPS, PharmD, Academic Fellow, Associate Chief Pharmacist, HTA, ESTAR Toscana, Via San Salvi 12, Firenze 50132, Italy. andrea.messori.it@gmail.com
Received: March 19, 2021
Peer-review started: March 19, 2021
First decision: May 6, 2021
Revised: May 9, 2021
Accepted: May 27, 2021
Article in press: May 27, 2021
Published online: July 20, 2021
Processing time: 121 Days and 12 Hours

Abstract

A “simplified” figure was proposed in 2011 to summarize the results of controlled trials that evaluate different treatments aimed at the same disease condition. The original criteria for classifying individual binary comparisons included superiority, inferiority and no significance difference; hence, they did not differentiate between no proof of difference vs proof of no difference. We updated the criteria employed in the original “simplified” figure in order to include this differentiation. A revised version of the simplified figure is proposed and described herein. An example of application is also presented. The example is focused on first-line treatments for paroxysmal atrial fibrillation. Three treatments (medical therapy, cryoballoon ablation, radiofrequency ablation) are compared with one another through direct and indirect comparisons.

Key Words: Randomised controlled trials; Outcome research; Meta-analysis; Direct comparisons; Indirect comparison; Statistics

Core Tip: A “simplified” figure was proposed in 2011 to summarize the results of controlled trials that evaluate different treatments aimed at the same disease condition. This graphical tool presents the network geometry along with the results of the analysis. The original criteria for classifying individual binary comparisons (direct or indirect comparisons) did not differentiate between no proof of difference vs proof of no difference. We have therefore updated the criteria employed in the original “simplified” figure to include this differentiation.



TO THE EDITOR

In 2011, Fadda and coworkers published in the BMJ the proposal of a simplified graph that, in the context of a network meta-analysis, presents the results of direct and indirect comparisons[1]. In 2019, another graph with very similar characteristics was proposed by De Vecchis et al[2]. Both of these graphs adopt the symbol “+” for superiority, “-“ for inferiority, and “=” for the remaining cases.

Differentiating between no proof of difference (with P > 0.05) and proof of no difference (with P > 0.05 and Pequivalence < 0.05) is increasingly recognised to be important[3]; the same applies to differentiation between no proof of difference and proof of non-inferiority (with P > 0.05 and Pnon-inferiority < 0.05, respectively). Since the two graphs of Fadda et al[1] and De Vecchis et al[2] do not include this differentiation, we propose to limit the symbol “=” to cases of equivalence and to adopt the symbol “NI” for non-inferiority or “ND” for the remaining cases. The suffix “t” remains useful because it identifies cases where the binary comparison shows a trend in favour of a treatment though in the absence of a statistically significant difference.

An example of the revisited graph is presented in Figure 1 that compares three first line treatments in paroxysmal atrial fibrillation[4-8].

Figure 1
Figure 1 Direct and indirect comparisons across three first-line treatments for patients with paroxysmal atrial fibrillation. The comparisons of radiofrequency vs medical therapy and cryoballoon vs medical therapy are based on three[4-6] and two trials[7,8], respectively.

In the field of network meta-analysis, the issue of graphical communication is complex, and the debate is still ongoing[9-15]. While the objective of describing the network geometry is quite straightforward[9,10], communication becomes more complex when it comes to presenting the results of the analysis[11-15]. The graphical proposal described herein is aimed at presenting the network geometry along with the results of the analysis. In our view, despite some unavoidable aspects of complexity, this tool deserves to be used particularly when the number of comparators is small.

Footnotes

Manuscript source: Unsolicited manuscript

Specialty type: Health care sciences and services

Country/Territory of origin: Italy

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Tsikopoulos K S-Editor: Ma YJ L-Editor: Filipodia P-Editor: Wang LYT

References
1.  Fadda V, Maratea D, Trippoli S, Messori A. Network meta-analysis. Results can be summarised in a simple figure. BMJ. 2011;342:d1555.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 28]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
2.  De Vecchis R, Ariano C, Rigopoulos A, Noutsias M. Graphical representation of network meta-analysis: an iconographic support to the complexity of multiple data comparisons. Eur J Clin Pharmacol. 2019;75:131-132.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
3.  Messori A, Fadda V, Gatto R, Maratea D, Trippoli S. Differentiating between "no proof of difference" and "proof of no difference" for new oral anticoagulants. BMJ. 2014;348:g1955.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
4.  Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, Pehrson S, Englund A, Hartikainen J, Mortensen LS, Hansen PS. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587-1595.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 474]  [Cited by in F6Publishing: 500]  [Article Influence: 41.7]  [Reference Citation Analysis (0)]
5.  Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD, Beresh H, Healey JS, Natale A;  RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014;311:692-700.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 432]  [Cited by in F6Publishing: 480]  [Article Influence: 48.0]  [Reference Citation Analysis (0)]
6.  Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis S, Rossillo A, Bonso A, Natale A. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293:2634-2640.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 787]  [Cited by in F6Publishing: 789]  [Article Influence: 41.5]  [Reference Citation Analysis (0)]
7.  Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, Niebauer M, Makati K, Halperin B, Gauri A, Morales G, Shao M, Cerkvenik J, Kaplon RE, Nissen SE;  STOP AF First Trial Investigators. Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Engl J Med. 2021;384:316-324.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 224]  [Cited by in F6Publishing: 366]  [Article Influence: 122.0]  [Reference Citation Analysis (0)]
8.  Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, Roux JF, Yung D, Skanes A, Khaykin Y, Morillo C, Jolly U, Novak P, Lockwood E, Amit G, Angaran P, Sapp J, Wardell S, Lauck S, Macle L, Verma A;  EARLY-AF Investigators. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2021;384:305-315.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 264]  [Cited by in F6Publishing: 424]  [Article Influence: 141.3]  [Reference Citation Analysis (0)]
9.  Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8:e76654.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1217]  [Cited by in F6Publishing: 1699]  [Article Influence: 154.5]  [Reference Citation Analysis (0)]
10.  IBM SPSS Statistics (Version 27.0.1.0)  Product documentation. [cited 9 May 2021]. Available from: https://www.ibm.com/docs/en/spss-statistics/26.0.0.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393:768-777.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 152]  [Cited by in F6Publishing: 182]  [Article Influence: 36.4]  [Reference Citation Analysis (0)]
12.  Veroniki AA, Straus SE, Rücker G, Tricco AC. Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis? J Clin Epidemiol. 2018;100:122-129.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 44]  [Cited by in F6Publishing: 45]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
13.  Seo M, Furukawa TA, Veroniki AA, Pillinger T, Tomlinson A, Salanti G, Cipriani A, Efthimiou O. The Kilim plot: A tool for visualizing network meta-analysis results for multiple outcomes. Res Synth Methods. 2021;12:86-95.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 11]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
14.  Seide SE, Jensen K, Kieser M. Utilizing radar graphs in the visualization of simulation and estimation results in network meta-analysis. Res Synth Methods. 2021;12:96-105.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 5]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
15.  Veroniki AA, Bender R, Glasziou P, Straus SE, Tricco AC. The number needed to treat in pairwise and network meta-analysis and its graphical representation. J Clin Epidemiol. 2019;111:11-22.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 33]  [Article Influence: 6.6]  [Reference Citation Analysis (0)]